Quick Answer: HIV medications split into two ACA coverage tracks in 2026. Pre-exposure prophylaxis (PrEP) drugs, Truvada, Descovy, Apretude, and Yeztugo, are a USPSTF Grade A preventive service, so ACA-compliant private plans and Medicare Part B must cover them at $0 with no deductible or copay, a mandate the Supreme Court upheld in the June 27, 2025 Kennedy v. Braidwood Management ruling. HIV treatment drugs, such as Biktarvy ($3,800 to $5,280 per month cash price), Genvoya, Triumeq, and Dovato, are covered as an Essential Health Benefit under 45 CFR 156.122, meaning marketplace and most employer plans must cover a range of antiretroviral classes, but patients still face formulary tiers, copays, and the 2026 Medicare Part D annual out-of-pocket cap of $2,100. Federal nondiscrimination rules under 45 CFR 156.125 and ACA Section 1557 bar insurers from placing every HIV drug on the highest specialty tier specifically to discourage enrollment by people with HIV, though enforcement varies by state. Medicaid covers HIV treatment and PrEP in every state, typically for $0 to $4 per prescription, and the Ryan White HIV/AIDS Program's state AIDS Drug Assistance Programs (ADAP) can pay marketplace premiums and cost-sharing for eligible low-income patients, a safety net that matters more in 2026 after enhanced ACA premium tax credits expired December 31, 2025 and raised average marketplace premiums by about 114 percent.
HIV medications fall into two categories with two different sets of ACA coverage rules. Pre-exposure prophylaxis (PrEP), the daily pill or periodic injection that prevents HIV infection in people who do not have HIV, includes Truvada, Descovy, Apretude, and the twice-yearly Yeztugo. Antiretroviral therapy (ART), the daily regimen for people already living with HIV, includes single-tablet combinations like Biktarvy, Genvoya, Triumeq, and Dovato, plus the long-acting injectable Cabenuva. The Affordable Care Act treats these two categories differently: PrEP is a preventive service covered at $0 under Public Health Service Act Section 2713, while ART is covered as an Essential Health Benefit subject to ordinary cost-sharing, formulary tiers, and the nondiscrimination protections described below.
Marketplace and most employer-sponsored plans must cover HIV treatment drugs under the Essential Health Benefits prescription-drug standard at 45 CFR 156.122, which requires each plan to cover at least one drug in every US Pharmacopeia category and class, or the same number as its EHB-benchmark plan, whichever is greater. A separate rule at 45 CFR 156.125 bars insurers from designing a formulary that discriminates against people with a specific chronic condition, and CMS guidance specifically flags placing all or most HIV drugs on the highest cost-sharing specialty tier as a practice that may discourage enrollment by people with HIV and violate that rule. The HIV+Hepatitis Policy Institute and other advocacy groups have repeatedly told CMS in comments on the annual Letter to Issuers, including for plan year 2026, that state regulators and CCIIO are not consistently enforcing this anti-tiering protection, so patients who see every antiretroviral on their plan's top specialty tier should file a formal complaint citing 45 CFR 156.125 rather than assume the design is automatically compliant.
Federal litigation and a subsidy cliff both reshaped HIV medication coverage heading into 2026. The Supreme Court ruled 6-3 on June 27, 2025 in Kennedy v. Braidwood Management that the US Preventive Services Task Force is constitutionally structured, preserving the ACA's $0 cost-sharing mandate for PrEP and roughly 100 million Americans' access to other no-cost preventive services nationwide. Separately, the ACA's enhanced premium tax credits, first added by the American Rescue Plan Act in 2021, expired on December 31, 2025 without a congressional extension, raising the average marketplace premium payment for subsidized enrollees by about 114 percent for 2026. That increase matters disproportionately for people living with HIV who rely on marketplace plans for treatment access, which is why state AIDS Drug Assistance Programs increasingly use Ryan White HIV/AIDS Program funds to pay marketplace premiums and cost-sharing on behalf of eligible clients rather than only supplying medication directly.
What HIV Medications & ACA Coverage Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same hiv medications & aca coverage can cost many times more at a hospital than at your local pharmacy:
2026 HIV Medications & ACA Coverage Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Pharmacy counter (retail, cash, no insurance) | $27 - $5,280/month depending on drug | Generic Truvada (PrEP) is cheapest at $27 - $70/month; brand HIV treatment drugs like Biktarvy run $3,800 - $5,280/month; see the comparison table below |
| ACA-compliant private plan (Marketplace or employer) | $0 for PrEP; formulary copay/coinsurance for treatment ART | PrEP is a $0 preventive service under PHS Act Section 2713; HIV treatment drugs are an Essential Health Benefit (45 CFR 156.122) subject to normal cost-sharing, but insurers cannot legally place every HIV drug on the top specialty tier under 45 CFR 156.125 |
| Medicare Part B / Part D (2026) | $0 for PrEP (Part B NCD); $0 - $460/month for treatment ART until the $2,100 annual Part D cap | PrEP moved from Part D to Part B with no cost-sharing effective September 30, 2024; treatment drugs remain ordinary Part D drugs, capped at $2,100/year for 2026 |
| Medicaid | $0 - $4/prescription for both PrEP and treatment | Every state Medicaid program covers HIV PrEP and treatment drugs; copay amounts vary modestly by state and are often $0 for expansion-population adults |
| Ryan White HIV/AIDS Program ADAP (premium and cost-sharing assistance) | $0 remaining balance for eligible low-income clients | State AIDS Drug Assistance Programs can pay Marketplace or employer-plan premiums, deductibles, and copays for HIV treatment for income-eligible clients, especially valuable after the 2026 premium tax credit changes |
Retail prices reflect 2026 GoodRx and manufacturer list-price data. Insurance and Medicare rows reflect ACA and Medicare coverage rules in effect for 2026; a copay charged for PrEP, or every HIV treatment drug placed on the highest formulary tier, is very likely a billing or benefit-design error rather than a valid coverage decision.
Source: CMS PrEP National Coverage Determination (2024), 45 CFR 156.122/156.125, CMS Medicare Part D/Part B benefit rules, GoodRx, HRSA Ryan White HIV/AIDS Program
Why Hospitals Charge So Much
Emergency departments and hospitals rarely dispense routine HIV medication refills, since both PrEP and antiretroviral treatment are self-managed outpatient regimens. A hospital that does provide a bridge supply, for example after a new HIV diagnosis or a same-day PrEP start following a risk assessment, typically adds a facility fee, a pharmacy dispensing fee, and a physician evaluation charge on top of the drug's acquisition cost, which is why a single dose given in a hospital-based clinic can be billed at several times the retail or ACA-covered price.
Hospitalized patients already taking HIV treatment face a separate risk: interrupted antiretroviral therapy. Hospitals sometimes fail to continue a patient's home ART regimen during an inpatient stay, substitute a different combination without the patient's input, or bill the continued medication at inpatient markup rates far above the $3,800-$5,280 monthly retail range for a drug like Biktarvy. Patients or family members should confirm with hospital pharmacy staff, in writing, that the exact home regimen continues unless a physician documents a specific clinical reason to change it, and should flag any inpatient antiretroviral charge for review using the medical bill analyzer.
HCPCS J-Codes: What Appears on Your Bill
Two cabotegravir-based injectables use similar but legally distinct HCPCS Level II J-codes, and mixing them up is a common source of coverage confusion. Apretude, used only for PrEP, and Cabenuva, used only for HIV treatment, are billed under different codes precisely because PrEP and treatment fall under different ACA and Medicare coverage rules.
HCPCS J-codes for HIV Medications & ACA Coverage| Code | Description | What to look for |
|---|
| J0739 | Injection, cabotegravir, extended-release, 1mg, for use only as HIV pre-exposure prophylaxis (Apretude) | Should process at $0 under the Medicare Part B PrEP National Coverage Determination; a charge or copay attached to this code is very likely a billing error |
| J0741 | Injection, cabotegravir and rilpivirine, extended-release, for HIV-1 treatment (Cabenuva) | Billed as ordinary HIV treatment under the medical or Part D benefit, not as a $0 preventive service; confirm your plan applied the correct formulary tier and that the claim was not denied by mistake as a preventive-service code |
Confusing J0739 (PrEP) and J0741 (treatment) can trigger an incorrect denial or an incorrect cost-sharing charge in either direction. Ask your clinic's billing office which code was submitted if you receive an unexpected bill for either drug.
Source: CMS HCPCS Quarterly Update; CMS PrEP National Coverage Determination
Patient Assistance Programs
Gilead Sciences and ViiV Healthcare each run manufacturer programs covering both sides of the HIV medication landscape, PrEP and treatment. A full breakdown of PrEP-specific manufacturer programs appears on CoveredUSA's HIV PrEP cost page; for HIV treatment drugs specifically, Gilead Advancing Access covers Biktarvy and Genvoya, and ViiV Healthcare's Patient Assistance Program through GSKPAF covers Triumeq, Dovato, and Cabenuva.
Patient assistance programs for HIV Medications & ACA Coverage| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Gilead Advancing Access (treatment) | Free Biktarvy or Genvoya for uninsured patients at or below approximately 500% FPL ($79,800 for a household of 1 in 2026); commercially insured patients can use a separate copay card | gileadadvancingaccess.com |
| ViiV Healthcare Patient Assistance Program (via GSKPAF) | Free Triumeq, Dovato, or Cabenuva for uninsured patients at or below approximately 500% FPL | gskpaf.org/viiv |
| State Ryan White Part B AIDS Drug Assistance Program (ADAP) | Pays for HIV treatment medication directly, or pays Marketplace/employer-plan premiums and cost-sharing, for income-eligible residents; income limits vary by state from about 200% to over 500% FPL | ryanwhite.hrsa.gov (find your state ADAP via nastad.org) |
| State Medicaid HIV drug coverage | Covers HIV treatment and PrEP for enrolled Medicaid beneficiaries at $0-$4 per prescription in every state | medicaid.gov |
| Federally Qualified Health Centers (sliding-fee scale) | Reduced-fee or free HIV treatment and PrEP prescribing at nearly 15,000 sites nationwide, regardless of insurance or immigration status | findahealthcenter.hrsa.gov |
Manufacturer copay cards for Biktarvy, Genvoya, Triumeq, Dovato, and Cabenuva cannot be used by Medicare, Medicaid, TRICARE, or VA beneficiaries under federal anti-kickback law (42 U.S.C. Section 1320a-7b). Those patients should rely on the 2026 Part D $2,100 annual cap, their state Medicaid benefit, or the income-based manufacturer patient assistance program instead of a commercial copay card.
Source: gileadadvancingaccess.com, gskpaf.org, ryanwhite.hrsa.gov, nastad.org, medicaid.gov, hrsa.gov
Medicare Part D
Medicare treats PrEP and HIV treatment drugs under two different benefits in 2026. PrEP moved entirely out of Part D and into Part B as a $0 preventive service after the September 30, 2024 National Coverage Determination, so no deductible, copay, or annual cap applies to Truvada, Descovy, Apretude, or Yeztugo. HIV treatment drugs like Biktarvy, Genvoya, Triumeq, and Dovato remain ordinary Part D drugs, meaning beneficiaries pay standard formulary-tier cost-sharing until they cross the 2026 annual Part D out-of-pocket cap of $2,100, after which the plan covers 100 percent of costs for the rest of the calendar year.
None of the antiretroviral drugs used for HIV treatment or PrEP has a Medicare Maximum Fair Price under the Inflation Reduction Act of 2022. CMS selected 10 drugs for the first round of negotiation, effective January 1, 2026, and 15 more for the second round, effective January 1, 2027; no HIV medication appears on either list. Extra Help, the Part D Low-Income Subsidy, can still substantially lower a Medicare beneficiary's HIV treatment cost-sharing below the standard formulary amount, and beneficiaries who also qualify for a state ADAP can have ADAP wrap around Part D to cover the remaining copay.
Common HIV Medications & ACA Coverage Billing Errors
HIV medication billing errors in 2026 usually trace to the PrEP-versus-treatment coverage split described above. Watch for these issues:
- A Marketplace or employer plan charging any deductible, copay, or coinsurance for Truvada, Descovy, or Apretude, which violates the ACA Section 2713 preventive-services mandate upheld by the Supreme Court in June 2025.
- A formulary that places every antiretroviral drug, across every HIV drug class, on the plan's highest specialty cost-sharing tier, a pattern CMS guidance flags as potentially discriminatory under 45 CFR 156.125.
- Prior authorization or step therapy required across an entire HIV drug class rather than for a specific drug with a documented clinical reason, another practice flagged as potentially discriminatory benefit design.
- Cabenuva (HIV treatment) billed under J0739 (the PrEP-only code) or Apretude (PrEP) billed under J0741 (the treatment-only code), which can trigger an incorrect coverage denial or cost-sharing charge.
- A manufacturer copay card applied for a Medicare, Medicaid, TRICARE, or VA beneficiary, which is prohibited by federal anti-kickback law and can result in a clawback of the claim later.
- ADAP or Ryan White premium payments not applied to a Marketplace bill before the patient is sent to collections, which can happen when a pharmacy or insurer's system does not recognize a third-party ADAP payment.
Frequently Asked Questions
Is there a generic for HIV treatment or PrEP medications in 2026?
It depends which category. Generic Truvada (emtricitabine/tenofovir DF) has been available for PrEP since October 2020, at $27 to $70 per month. None of the four leading HIV treatment drugs discussed here, Biktarvy, Genvoya, Triumeq, or Dovato, has a US generic as of 2026; each is a patent-protected combination pill, with Biktarvy's generic not expected before roughly 2036 under current patent settlements. Descovy, Apretude, and Yeztugo (PrEP) also have no generic yet; see CoveredUSA's HIV PrEP cost page for those specific timelines.
How do I apply for a patient assistance program for HIV treatment drugs like Biktarvy or Triumeq in 2026?
Apply directly to the manufacturer. Gilead Advancing Access covers Biktarvy and Genvoya, and the ViiV Healthcare Patient Assistance Program through GSKPAF covers Triumeq, Dovato, and Cabenuva, both for uninsured patients at or below approximately 500 percent of the federal poverty level. You can also apply through your state's Ryan White Part B AIDS Drug Assistance Program (ADAP), found via nastad.org, which can pay for the medication directly or pay your Marketplace premium and cost-sharing instead.
Can I use a manufacturer savings card for HIV medication with Medicare or Medicaid?
No. Federal anti-kickback law bars manufacturer copay cards for Biktarvy, Genvoya, Triumeq, Dovato, and Cabenuva from being used by Medicare, Medicaid, TRICARE, or VA beneficiaries. Medicare beneficiaries instead rely on the 2026 Part D annual out-of-pocket cap of $2,100, Extra Help if income-eligible, or a state Ryan White ADAP that wraps around Part D to cover remaining copays.
What if my ACA marketplace plan puts all my HIV drugs on the highest cost-sharing tier or denies coverage?
Request a written denial notice, then cite 45 CFR 156.122 and 45 CFR 156.125, the Essential Health Benefits and nondiscriminatory benefit-design rules, in a formal appeal; CMS guidance specifically flags placing every HIV drug on the top specialty tier as potentially discriminatory. If the plan does not correct the issue, escalate to your state Department of Insurance and consider filing a complaint with an HIV advocacy organization that tracks discriminatory formulary design.
Does the IRA negotiated Medicare price apply to any HIV medication in 2026?
No. None of the 10 drugs negotiated for 2026 or the 15 drugs selected for the second round effective 2027 is an HIV treatment or PrEP drug. No antiretroviral, whether Biktarvy, Genvoya, Triumeq, Dovato, Truvada, Descovy, or Apretude, carries a Medicare Maximum Fair Price as of 2026. Medicare beneficiaries taking HIV treatment drugs rely instead on standard Part D formulary rules and the 2026 annual out-of-pocket cap of $2,100.
What does HIV treatment cost without insurance at the pharmacy counter in 2026?
Brand HIV treatment regimens run high without coverage. Biktarvy costs $3,800 to $5,280 for a 30-day cash supply, and similar single-tablet regimens like Genvoya, Triumeq, and Dovato fall in a comparable range. By contrast, PrEP is far cheaper: generic Truvada costs $27 to $70 per month. Uninsured patients facing these treatment-drug prices should apply for Gilead Advancing Access, the ViiV Healthcare PAP, or their state Ryan White ADAP rather than paying cash.
Do I qualify for Ryan White ADAP or a manufacturer patient assistance program based on my income?
Manufacturer programs from Gilead and ViiV generally use an approximately 500 percent federal poverty level threshold, which is $79,800 for a household of one and $165,000 for a household of four in 2026. State Ryan White ADAP income limits are set individually by each state and range from about 200 percent to over 500 percent FPL, so check your specific state's ADAP through nastad.org, since thresholds and required documentation differ from the manufacturer programs.
What's the difference between how the ACA covers PrEP versus HIV treatment drugs?
PrEP is legally a preventive service under Public Health Service Act Section 2713, based on a USPSTF Grade A recommendation, so ACA-compliant plans must cover Truvada, Descovy, Apretude, and Yeztugo at $0 with no deductible or copay. HIV treatment drugs like Biktarvy are covered instead as an Essential Health Benefit under 45 CFR 156.122, meaning plans must offer a range of antiretroviral classes but can still apply normal deductibles, copays, and formulary tiers, subject to the nondiscrimination limits in 45 CFR 156.125.
